ImmuPharma (LON:IMM) Trading Up 9.5% - What's Next?

Key Points

• Shares of ImmuPharma plc rose by 9.5%, trading as high as GBX 14.20 ($0.19) during the day, with a significant trading volume increase of 176% compared to its average.
• The company reported a quarterly earnings loss of GBX (0.38) per share, with analysts forecasting negative earnings for the current fiscal year.
• ImmuPharma specializes in developing peptide-based therapeutics, including treatments for autoimmune diseases, with its lead program being Lupuzor™ for Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) were up 9.5% during mid-day trading on Tuesday . The stock traded as high as GBX 14.20 ($0.19) and last traded at GBX 12.10 ($0.16). Approximately 23,646,498 shares were traded during trading, an increase of 176% from the average daily volume of 8,583,096 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Stock Up 9.5%

The firm has a fifty day simple moving average of GBX 4.66 and a 200-day simple moving average of GBX 3.39. The company has a market cap of £60.47 million, a PE ratio of -1,359.55 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.